Movement Alert｜Boston Scientific Rises 3.53% in Regular Trading, Oversold Bounce as Most Analysts Maintain Buy Ratings Despite Target Cuts

Market Focus08-06

On August 6, Boston Scientific rose 3.53% in regular trading, trading at approximately $49.16 per share, with turnover of $33.86 million. The stock rebounded after falling 3.03% in the prior session amid ongoing pressure from a full-year guidance cut and multiple target price reductions.

On the news front, the bounce was supported by the fact that despite significant target price cuts, the majority of covering analysts maintained buy ratings. Deutsche Bank lowered its target from $75 to $60, UBS from $74 to $67, and RBC from $85 to $70, all retaining buy or outperform recommendations. UBS highlighted underappreciated growth drivers including coronary intravascular lithotripsy and renal denervation products expected in 2027-2028, representing a combined $2.5 billion addressable market, along with the Empower leadless pacemaker launch in 2027. UBS noted that current share pricing implies sales declines through 2029, which it views as overly pessimistic given the company's pipeline beyond its challenged Watchman and electrophysiology franchises.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108942440?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108942440","market":"us","top_or_hot":-1,"title":"Movement Alert｜Boston Scientific Rises 3.53% in Regular Trading, Oversold Bounce as Most Analysts Maintain Buy Ratings Despite Target Cuts","media":"Market Focus","content":"<p><p>On August 6, Boston Scientific rose 3.53% in regular trading, trading at approximately $49.16 per share, with turnover of $33.86 million. The stock rebounded after falling 3.03% in the prior session amid ongoing pressure from a full-year guidance cut and multiple target price reductions.</p><p>On the news front, the bounce was supported by the fact that despite significant target price cuts, the majority of covering analysts maintained buy ratings. Deutsche Bank lowered its target from $75 to $60, UBS from $74 to $67, and RBC from $85 to $70, all retaining buy or outperform recommendations. UBS highlighted underappreciated growth drivers including coronary intravascular lithotripsy and renal denervation products expected in 2027-2028, representing a combined $2.5 billion addressable market, along with the Empower leadless pacemaker launch in 2027. UBS noted that current share pricing implies sales declines through 2029, which it views as overly pessimistic given the company's pipeline beyond its challenged Watchman and electrophysiology franchises.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Boston Scientific Rises 3.53% in Regular Trading, Oversold Bounce as Most Analysts Maintain Buy Ratings Despite Target Cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Boston Scientific Rises 3.53% in Regular Trading, Oversold Bounce as Most Analysts Maintain Buy Ratings Despite Target Cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-06 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 6, Boston Scientific rose 3.53% in regular trading, trading at approximately $49.16 per share, with turnover of $33.86 million. The stock rebounded after falling 3.03% in the prior session amid ongoing pressure from a full-year guidance cut and multiple target price reductions.</p><p>On the news front, the bounce was supported by the fact that despite significant target price cuts, the majority of covering analysts maintained buy ratings. Deutsche Bank lowered its target from $75 to $60, UBS from $74 to $67, and RBC from $85 to $70, all retaining buy or outperform recommendations. UBS highlighted underappreciated growth drivers including coronary intravascular lithotripsy and renal denervation products expected in 2027-2028, representing a combined $2.5 billion addressable market, along with the Empower leadless pacemaker launch in 2027. UBS noted that current share pricing implies sales declines through 2029, which it views as overly pessimistic given the company's pipeline beyond its challenged Watchman and electrophysiology franchises.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1108942440","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108942440","pubTimestamp":1786023168,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 6, Boston Scientific rose 3.53% in regular trading, trading at approximately $49.16 per share, with turnover of $33.86 million. The stock rebounded after falling 3.03% in the prior session...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"走势警报|波士顿科学公司常规交易中上涨 3.53%，超卖反弹，尽管目标下调，大多数分析师仍维持买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"On August 6, Boston Scientific rose 3.53% in regular trading, trading at approximately $49.16 per share, with turnover of $33.86 million. The stock rebounded after falling 3.03% in the prior session amid ongoing pressure from a full-year guidance cut and multiple target price reductions.On the news front, the bounce was supported by the fact that despite significant target price cuts, the majority of covering analysts maintained buy ratings. Deutsche Bank lowered its target from $75 to $60, UBS from $74 to $67, and RBC from $85 to $70, all retaining buy or outperform recommendations. UBS highlighted underappreciated growth drivers including coronary intravascular lithotripsy and renal denervation products expected in 2027-2028, representing a combined $2.5 billion addressable market, along with the Empower leadless pacemaker launch in 2027. UBS noted that current share pricing implies sales declines through 2029, which it views as overly pessimistic given the company's pipeline beyond its challenged Watchman and electrophysiology franchises.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108942440","isCrawlerRequest":true}